- Report
- August 2025
- 191 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 188 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 196 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 184 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 189 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 197 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 183 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 190 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 182 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 197 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- August 2025
- 185 Pages
Global
From €3161EUR$3,545USD£2,730GBP
€3512EUR$3,939USD£3,033GBP
- Report
- May 2026
- 224 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 235 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 374 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 380 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 419 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 577 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 578 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 184 Pages
Global
From €5216EUR$5,850USD£4,505GBP
- Report
- May 2026
- 360 Pages
Global
From €5216EUR$5,850USD£4,505GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more